Accessibility Menu
Precigen Stock Quote

Precigen (NASDAQ: PGEN)

$3.94
(-3.6%)
-0.14
Price as of October 22, 2025, 3:58 p.m. ET

KEY DATA POINTS

Current Price
$3.91
Daily Change
(-3.6%) $0.14
Day's Range
$3.85 - $4.18
Previous Close
$3.91
Open
$4.12
Beta
1.70
Volume
4,312,086
Average Volume
9,217,382
Market Cap
1.2B
Market Cap / Employee
$4.08M
52wk Range
$0.65 - $5.23
Revenue
-
Gross Margin
-0.30%
Dividend Yield
N/A
EPS
-$0.43
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Precigen Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
PGEN+317.2%-10.93%-2.29%-83%
S&P+15.06%+95.03%+14.29%+297%

Precigen Company Info

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

News & Analysis

The Fool has written over 100 articles on Precigen.

Financial Health

General

Q2 2025YOY Change
Revenue$0.86M19.4%
Gross Profit-$0.55M63.2%
Gross Margin-64.72%145.2%
Market Cap$419.16M5.1%
Market Cap / Employee$2.93M0.0%
Employees143-29.2%
Net Income-$26.64M54.7%
EBITDA-$27.23M-10.2%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$13.76M47.2%
Accounts Receivable$0.33M-36.0%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$4.22M-16.7%
Short Term Debt$0.93M-26.7%

Ratios

Q2 2025YOY Change
Return On Assets-142.24%-45.8%
Return On Invested Capital-78.72%-22.8%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$19.94M21.6%
Operating Free Cash Flow-$18.98M17.9%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book5.545.9211.33-29.81-831.39%
Price to Sales65.9383.57104.2396.996.76%
Price to Tangible Book Value18.1812.7729.25-11.23-190.13%
Enterprise Value to EBITDA-11.58-11.95-17.87-14.59-6.53%
Return on Equity-137.5%-136.3%-278.5%-668.0%416.58%
Total Debt$5.75M$5.50M$5.42M$5.15M-18.74%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.